Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Key Inclusion Criteria:

• Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer
• Complete or partial response following standard of care surgery and first line chemotherapy
• May have one disease recurrence with complete or partial response or stable disease following standard of care second line care treatment
• Previous investigational biologic therapy allowed, must be more than 56 days prior to first injection
• Previous treatment with bisphosphonate allowed, must be completed 14 days prior to first injection
• Ambulatory with an ECOG 0-1
• Life expectancy > 6 months
• Meet protocol-specified lab requirements
• Provide informed consent and have ability to comply with protocol requirements

Key Exclusion Criteria:

• Concurrent chemotherapy, radiation therapy, immunotherapy are excluded (washout periods as specified in protocol)
• Prior receipt of survivin based vaccines
• Participation in prior therapeutic adjuvant ovarian cancer studies, except for platinum-based adjuvant studies
• Progressive disease (rising CA-125 acceptable)
• More than one course of chemotherapy for recurrent disease
• Concurrent bevacizumab as maintenance therapy
• Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
• History of autoimmune disease
• Recent history of thyroiditis
• Presence of a serious acute infection or chronic infection
• Brain metastases
• Other serious intercurrent chronic or acute illness
• Ongoing treatment with steroid therapy or other immunosuppressive
• Acute or chronic skin disorders